STAT
JULY 20, 2024
First Opinion is STAT’s platform for interesting, illuminating, and maybe even provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others. To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected Letters to the Editor received in response to them.
Drug Patent Watch
JULY 20, 2024
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Happy PharmD
JULY 20, 2024
Are you curious about emergency medicine pharmacy and whether or not it’s something that you should consider as a career choice? Well, you’re not alone. Lots of other people have thought the same thing, and in this discussion, we’ll dive into the nitty-gritty details — the pros, the cons, the salary, the satisfaction, the job demand, and of course, the flexibility of having this career path as a pharmacist.
PharmaTech
JULY 20, 2024
PluriCDMO, Pluri's newly launched CMDO division, has been selected by Kadimastem to manufacture two novel cell therapy product candidates.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Patent Watch
JULY 20, 2024
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Romania.
Pharmacy Times
JULY 20, 2024
However, the cost of zuranolone makes it challenging to access and justify, given study results comparing it with brexanolone.
Expert insights. Personalized for you.
264 
Let's personalize your content